S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Dr. Reddy's Laboratories (RDY) Stock Forecast & Price Target

$68.86
-0.89 (-1.28%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$68.51
$69.57
50-Day Range
$64.27
$69.90
52-Week Range
$51.11
$73.17
Volume
409,700 shs
Average Volume
245,377 shs
Market Capitalization
$11.49 billion
P/E Ratio
18.56
Dividend Yield
0.60%
Price Target
$70.00

Dr. Reddy's Laboratories Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$70.00
1.66% Upside
High Forecast$70.00
Average Forecast$70.00
Low Forecast$70.00
TypeCurrent Forecast
12/11/22 to 12/11/23
1 Month Ago
11/11/22 to 11/11/23
3 Months Ago
9/12/22 to 9/12/23
1 Year Ago
12/11/21 to 12/11/22
Consensus Rating
Hold
Reduce
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$70.00$70.00$70.00$67.00
Predicted Upside1.66% Upside26.83% Upside26.74% Upside21.22% Upside
Get Dr. Reddy's Laboratories Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.


RDY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RDY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dr. Reddy's Laboratories Stock vs. The Competition

TypeDr. Reddy's LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.67
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside1.66% Upside733.14% Upside13.58% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/29/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
6/1/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$67.00 ➝ $70.00+26.83%
5/18/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
3/17/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
1/30/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:30 AM ET.












RDY Price Target - Frequently Asked Questions

What is Dr. Reddy's Laboratories's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Dr. Reddy's Laboratories stock is Hold based on the current 1 sell rating, 2 hold ratings and 1 buy rating for RDY. The average twelve-month price prediction for Dr. Reddy's Laboratories is $70.00 with a high price target of $70.00 and a low price target of $70.00. Learn more on RDY's analyst rating history.

Do Wall Street analysts like Dr. Reddy's Laboratories more than its competitors?

Analysts like Dr. Reddy's Laboratories less than other Medical companies. The consensus rating for Dr. Reddy's Laboratories is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how RDY compares to other companies.

Does Dr. Reddy's Laboratories's stock price have much upside?

According to analysts, Dr. Reddy's Laboratories's stock has a predicted upside of 26.83% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NYSE:RDY) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -